Hughes M, Herrick AL. Systemic sclerosis. Br J Hosp Med. 2019;80(9):530–6.
Denton CP, Wells AU, Coghlan JG. Major lung complications of systemic sclerosis. Nat Rev Rheumatol. 2018;14(9):511–27.
Gayle A, Schoof N, Alves M, Clarke D, Raabe C, Das P, et al. Healthcare resource utilization among patients in England with systemic sclerosis-associated interstitial lung disease: a retrospective database analysis. Adv Ther. 2020;37(5):2460–76.
Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897–905.
Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol. 2007;34(5):1194–200.
Kafaja S, Clements PJ, Wilhalme H, Tseng C-H, Furst DE, Kim GH, et al. Reliability and minimal clinically important differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med. 2018;197(5):644–52.
Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, et al. Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - report from OMERACT CTD-ILD Working Group. J Rheumatol. 2015;42(11):2168–71.
Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017;69(8):1670–8.
Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, et al. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J. 2016;47(2):597–606.
Mittoo S, Frankel S, LeSage D, Strand V, Shah AA, Christopher-Stine L, et al. Patient perspectives in OMERACT provide an anchor for future metric development and improved approaches to healthcare delivery in connective tissue disease related interstitial lung disease (CTD-ILD). Curr Respir Med Rev. 2015;11(2):175–83.
Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax. 2014;69(5):428–36.
Saketkoo LA, Scholand MB, Lammi MR, Russell A-M. Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials. J Scleroderma Relat Disord. 2020;5(2 Suppl):48–60.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–28.
Kreuter M, Hoffmann-Vold A-M, Matucci-Cerinic M, Saketkoo L, Highland K, Wilson H, et al. Health-related quality of life in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): impact of lung function on patient-reported outcomes in a randomized phase III trial. Arthritis Rheumatol. 2019;71(Suppl):1656.
Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019;20(1):59.
Fischer A, Kong AM, Swigris JJ, Cole AL, Raimundo K. All-cause healthcare costs and mortality in patients with systemic sclerosis with lung involvement. J Rheumatol. 2018;45(2):235–41.
Zhou Z, Fan Y, Thomason D, Tang W, Liu X, Zhou Z-Y, et al. Economic burden of illness among commercially insured patients with systemic sclerosis with interstitial lung disease in the USA: a claims data analysis. Adv Ther. 2019;36(5):1100–13.
Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population. J Rheumatol. 2012;39(12):2303–9.
Molenberghs G, Alonso A, Van der Elst W, Burzykowski T, Buyse M. Statistical evaluation of surrogate endpoints in clinical studies. In: Young W, Chen DG, editors. Clinical Trial Biostatistics and Biopharmaceutical Applications. New York: Chapman and Hall/CRC; 2014.
Papageorgiou G, Mauff K, Tomer A, Rizopoulos D. An overview of joint modeling of time-to-event and longitudinal outcomes. Annu Rev Stat Appl. 2019;6(1):223–40.
Chen Y, Postmus D, Cowie MR, Woehrle H, Wegscheider K, Simonds AK, et al. Using joint modelling to assess the association between a time-varying biomarker and a survival outcome: an illustrative example in respiratory medicine. Eur Respir J. 2021;57(2):2003206.
Taylor RS, Elston J. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. Health Technol Assess. 2009;13(8):iii ix-xi, 1-50.
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–47.
Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada YMRM, Draeger H, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthr Res Ther. 2010;12(5):R166.
Garcia-Hernandez A, Rizopoulos D. %JM: a SAS macro to fit jointly generalized mixed models for longitudinal data and time-to-event responses. J Stat Softw. 2018;84(12):29.
Rizopoulos D. JM: an R package for the joint modelling of longitudinal and time-to-event data. J Stat Softw. 2010;35(9):33.
Sudell M, Kolamunnage-Dona R, Tudur-Smith C. Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis. BMC Med Res Methodol. 2016;16(1):168.
Lassenius MI, Toppila I, Pontynen N, Kasslin L, Kaunisto J, Kilpelainen M, et al. Forced vital capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis. Eur Clin Respir J. 2020;7(1):1702618.